{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:52:27Z","timestamp":1792266747581,"version":"4.4.0"},"reference-count":114,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent. Combined-modality schedules (ABVD plus radiotherapy) in early-stage disease, along with treatment intensity adaptation to early metabolic response assessed by PET\/CT in advanced stage HL, have been the cornerstones of risk stratification and treatment decision-making, minimizing treatment-related complications while keeping efficacy. Nevertheless, a non-negligible number of patients are primary refractory or relapse after front-line treatment. Novel immunotherapeutic agents, namely Brentuximab Vedotin (BV) and immune checkpoint inhibitors (CPI), have already shown outstanding efficacy in a relapsed\/refractory setting in recent landmark studies. Several phase 2 single-arm studies suggest that the addition of these agents in the frontline setting could further improve long-term disease control permitting one to reduce the exposure to cytotoxic drugs. However, a longer follow-up is needed. At the time of this writing, the only randomized phase 3 trial so far published is the ECHELON-1, which compares 1 to 1 BV-AVD (Bleomycin is replaced by BV) with standard ABVD in untreated advanced-stage III and IV HL. The ECHELON-1 trial has proven that BV-AVD is safe and more effective both in terms of long-term disease control and overall survival. Just recently, the results of the S1826 SWOG trial demonstrated that the combination nivolumab-AVD (N-AVD) is better than BV-AVD, while preliminary results of other randomized ongoing phase 3 trials incorporating anti-PD-1 in this setting will be soon available. The aim of this review is to present the recent data regarding these novel agents in first-line treatment of HL and to highlight current and future trends which will hopefully reshape the overall management of this disease.<\/jats:p>","DOI":"10.3390\/ijms241713187","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:25:33Z","timestamp":1692951933000},"page":"13187","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-1853","authenticated-orcid":false,"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Liaskas","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Pereyra","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Alejandro Posadas, Buenos Aires 1684, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Panayiotidis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[{"name":"Research and Clinical Innovation Department, Antoine Lacassagne Cancer Center, 06100 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"Kuppers","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg cells in Hodgkin\u2019s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_9","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: A 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2013.02.002","article-title":"Advanced and relapsed\/refractory Hodgkin lymphoma: What has been achieved during the last 50 years","volume":"50","author":"Vassilakopoulos","year":"2013","journal-title":"Semin. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: Final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.1988.6.2.239","article-title":"Clinical stages I and II Hodgkin\u2019s disease: A specifically tailored therapy according to prognostic factors","volume":"6","author":"Carde","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.1993.11.11.2258","article-title":"Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin\u2019s disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group","volume":"11","author":"Carde","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andre","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.1998.16.1.19","article-title":"MOPP\/ABV hybrid chemotherapy for advanced Hodgkin\u2019s disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial","volume":"16","author":"Glick","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin\u2019s lymphoma: A study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: A systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/j.seminhematol.2016.05.006","article-title":"Treatment of advanced-stage Hodgkin lymphoma","volume":"53","author":"Vassilakopoulos","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","article-title":"Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses","volume":"152","author":"Gallamini","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early Chemotherapy Intensification with Escalated BEACOPP in Patients with Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma with Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL\/FIL HD0607 Trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2017-05-784678","article-title":"Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma","volume":"130","author":"Connors","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.3163_5","article-title":"Nivolumab (N)-AVD improves progression-free survival compared to Brentuximab Vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin Lymphoma (HL): Results of SWOG S1826","volume":"41","author":"Herrera","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.HS9.0000890572.92604.2c","article-title":"T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: Results from the very early PET-response adapted EORTC-COBRA trial","volume":"6","author":"Diepstra","year":"2022","journal-title":"HemaSphere"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","article-title":"Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin\u2019s lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): An open-label, international, randomised phase 3 study by the German Hodgkin Study Group","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: Final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41375-021-01386-z","article-title":"Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: Follow-up analysis of a randomized phase II study from the German Hodgkin Study Group","volume":"36","author":"Damaschin","year":"2022","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2022-165917","article-title":"Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial by the German Hodgkin Study Group","volume":"140","author":"Borchmann","year":"2022","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hon.3196_LBA5","article-title":"BRECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin Lymphoma: Efficacy results of the GHSG phase III HD21 trial","volume":"41","author":"Borchmann","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","article-title":"ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma","volume":"4","author":"Park","year":"2020","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.18.01799","article-title":"Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study","volume":"37","author":"Barrington","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2022-156382","article-title":"Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2","volume":"140","author":"Stuver","year":"2022","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/10428194.2019.1702178","article-title":"Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and\/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis","volume":"61","author":"Zinzani","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Armand, P., Zinzani, P.L., Lee, H.J., Johnson, N.A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T.P., and Tomita, A. (2023). Five-year follow-up of KEYNOTE-087: Pembrolizumab monotherapy in relapsed\/refractory classical Hodgkin lymphoma. Blood.","DOI":"10.1182\/blood.2022019386"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1470-2045(21)00138-8","article-title":"Relapsed or refractory classical Hodgkin lymphoma: Which immunotherapy, and when?","volume":"22","author":"Vassilakopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hon.74_2879","article-title":"Nivolumab for Relapsed or Refractory (R\/R) Classical Hodgkin Lymphoma (Chl) after Autologous Transplantation: 5-Year Overall Survival from the Phase 2 Checkmate 205 Study","volume":"39","author":"Ansell","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","volume":"41","author":"Brockelmann","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv."},{"key":"ref_74","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Brockelmann","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2021-144610","article-title":"Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma","volume":"138","author":"Lynch","year":"2021","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: Final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2022-163787","article-title":"Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study","volume":"140","author":"Advani","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/bloodadvances.2021004511","article-title":"Avelumab in relapsed\/refractory classical Hodgkin lymphoma: Phase 1b results from the JAVELIN Hodgkins trial","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/hon.3163_108","article-title":"Avelumab Monotherapy Followed by a Pet Adapted Chemotherapy Approach in the First Line Treatment of Classical Hodgkin Lymphoma: Initial Results from the Avenue Window Study","volume":"41","author":"Collins","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.12759","article-title":"Current status of prognostication in classical Hodgkin lymphoma","volume":"165","author":"Venkataraman","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2016.05.003","article-title":"Prognostic factors in Hodgkin lymphoma","volume":"53","author":"Brockelmann","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2022-156553","article-title":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9399","DOI":"10.1182\/blood-2022-156576","article-title":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood-2022-159258","article-title":"Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma","volume":"140","author":"Park","year":"2022","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2023.01.014","article-title":"Characteristics and Outcomes of Older Patients with Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study","volume":"23","author":"Goh","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_92","first-page":"87","article-title":"Hodgkin Lymphoma (HL) in patients \u226560 years old: Clinical and laboratory features, outcome after anthracycline-based treatment and comparison with younger patients: A single center experience","volume":"96","author":"Vassilakopoulos","year":"2011","journal-title":"Haematol. Hematol. J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u2265 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients with Untreated Classical Hodgkin Lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.17073","article-title":"Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)","volume":"193","author":"Gibb","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Holkova","year":"2015","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u2265 60 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/JCO.2020.38.15_suppl.8029","article-title":"Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO Trial)","volume":"38","author":"Viviani","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136583","article-title":"Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients","volume":"136","author":"Yasenchak","year":"2020","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): A multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study","volume":"138","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hon.3163_106","article-title":"Pembrolizumab as First Therapy for Hodgkin Lymphoma Is Deliverable in Older or Abvd-Ineligible Patients, Allows Subsequent Therapy, and Gives Adequate Survival","volume":"41","author":"Dickinson","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.3163_107","article-title":"Phase 2 Trial of Nivolumab Plus Adriamycin, Vinblastine, Dacarbazine (N-Avd) as Frontline Therapy in Older Adults with Hodgkin Lymphoma","volume":"41","author":"Torka","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_106","first-page":"14","article-title":"Very Late Relapses in Hodgkin Lymphoma: A Critical Comparison of Major Published Studies","volume":"13","author":"Liaskas","year":"2022","journal-title":"Haema"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: Results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.HS9.0000890820.12468.10","article-title":"P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma\u2014The Investigator-Initiated Phase II GHSG INDIE Trial","volume":"6","author":"Kaul","year":"2022","journal-title":"HemaSphere"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000890668.27643.97","article-title":"P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD\u00b1ISRT with brentuximab vedotin+AVD\u00b1ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma","volume":"6","author":"Radford","year":"2022","journal-title":"HemaSphere"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.HS9.0000890652.56016.97","article-title":"T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2\u2014RAFTING Trial","volume":"6","author":"Gallamini","year":"2022","journal-title":"HemaSphere"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-022-00674-w","article-title":"Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: Linear pattern and distinct prognostic factors","volume":"12","author":"Vassilakopoulos","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.18180","article-title":"Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma\u2014A study from the Danish Lymphoma Registry","volume":"198","author":"Andersen","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials","volume":"35","author":"Brockelmann","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:39Z","timestamp":1760128719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/17\/13187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":114,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241713187"],"URL":"https:\/\/doi.org\/10.3390\/ijms241713187","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}